Decreased levels of SMN result, instead, in a reduction of its chaperone-like activity against mutant SOD1-mediated toxicity in vitro, contributing to increase-free radical injury and oxidative stress, two well-established features of ALS [54]. This evidence concerns the gene SMN2 and amyotrophic lateral sclerosis.